EUROFARMA Trademark

Trademark Overview

On Thursday, July 9, 2020, a trademark application was filed for EUROFARMA with the United States Patent and Trademark Office. The USPTO has given the EUROFARMA trademark a serial number of 90043411. The federal status of this trademark filing is REGISTERED as of Tuesday, December 7, 2021. This trademark is owned by EUROFARMA LABORATÓRIOS S.A.. The EUROFARMA trademark is filed in the Pharmaceutical Products, Advertising and Business and Retail Services categories with the following description:

Medicinal preparations for treating diseases of the nervous system, central nervous system, and diabetes for use in human medicine

Providing commercial information in the field pharmaceuticals for treating diseases of the nervous system and central nervous system for humans
eurofarma

General Information

Serial Number90043411
Word MarkEUROFARMA
Filing DateThursday, July 9, 2020
Status700 - REGISTERED
Status DateTuesday, December 7, 2021
Registration Number6579000
Registration DateTuesday, December 7, 2021
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, September 21, 2021

Trademark Statements

Indication of Colors claimedColor is not claimed as a feature of the mark.
Description of MarkThe mark consists of the stylized wording "EUROFARMA" to the right of a globe featuring meridian lines on the right half and three stacked horizontal bars spaced apart on the left half. The color gray in the mark is for shading purposes only and is not a part of the mark.
Goods and ServicesMedicinal preparations for treating diseases of the nervous system, central nervous system, and diabetes for use in human medicine
Goods and ServicesProviding commercial information in the field pharmaceuticals for treating diseases of the nervous system and central nervous system for humans
Translation of Words in MarkThe wording "EUROFARMA" has no meaning in a foreign language.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, August 5, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class035 - Advertising; business management; business administration; office functions.
US Class Codes100, 101, 102
Class Status Code6 - Active
Class Status DateWednesday, August 5, 2020
Primary Code035
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameEUROFARMA LABORATÓRIOS S.A.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSÃO PAULO 04603-003
BR
Party NameEUROFARMA LABORATÓRIOS S.A.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSÃO PAULO 04603-003
BR
Party NameEUROFARMA LABORATÓRIOS S.A.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSÃO PAULO 04603-003
BR

Trademark Events

Event DateEvent Description
Tuesday, December 7, 2021REGISTERED-PRINCIPAL REGISTER
Tuesday, September 21, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 21, 2021PUBLISHED FOR OPPOSITION
Wednesday, September 1, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Saturday, August 14, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, August 14, 2021EXAMINER'S AMENDMENT ENTERED
Saturday, August 14, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Saturday, August 14, 2021EXAMINERS AMENDMENT E-MAILED
Saturday, August 14, 2021EXAMINERS AMENDMENT -WRITTEN
Saturday, August 14, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, August 13, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, August 13, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, August 12, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, August 12, 2021NON-FINAL ACTION E-MAILED
Thursday, August 12, 2021NON-FINAL ACTION WRITTEN
Wednesday, July 7, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, July 6, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, July 6, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, July 7, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, July 7, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, July 6, 2021ASSIGNED TO LIE
Saturday, July 3, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, July 3, 2021NON-FINAL ACTION E-MAILED
Saturday, July 3, 2021NON-FINAL ACTION WRITTEN
Friday, May 28, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, May 27, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, May 27, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, May 26, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, May 26, 2021NON-FINAL ACTION E-MAILED
Wednesday, May 26, 2021NON-FINAL ACTION WRITTEN
Tuesday, May 4, 2021TEAS VOLUNTARY AMENDMENT RECEIVED
Thursday, April 22, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, April 21, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, April 21, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, April 20, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, April 20, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, April 20, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, October 23, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, October 23, 2020NON-FINAL ACTION E-MAILED
Friday, October 23, 2020NON-FINAL ACTION WRITTEN
Tuesday, October 20, 2020ASSIGNED TO EXAMINER
Thursday, August 6, 2020NOTICE OF DESIGN SEARCH CODE E-MAILED
Wednesday, August 5, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, July 21, 2020TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Tuesday, July 21, 2020TEAS VOLUNTARY AMENDMENT RECEIVED
Monday, July 13, 2020NEW APPLICATION ENTERED IN TRAM

Related Keywords

eurofarma system nervous central diseases treating information field humans commercial pharmaceuticals